SynthesisFrontiers in pharmacology2025
What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite significant survival improvements from third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), almost all patients eventually develop resistance. Currently, some studies have confirmed that combination therapy regimens based on third-generation EGFR-TKIs can further enhance efficacy. However, it remains unknown which specific combination regimen is more effective. Methods: Randomized clinical trials comparing combination treatments involving third-generation EGFR-TKIs vs. EGFR-TKI single agent for advanced EGFR-mutated NSCLC patients were included. The primary outcome was progression-free survival (PFS), while secondary outcomes included overall survival (OS), objective response rate (ORR) and treatment-related adverse events (TRAEs). Subgroup analyses were also conducted. Results: The study encompassed 5 trials, involving 1791 patients. The combination of osimertinib with chemotherapy and with ramucirumab, as well as the combination of lazertinib with amivantamab, have been shown to significantly improve PFS compared to osimertinib monotherapy. The combination of osimertinib with chemotherapy and the combination of lazertinib with amivantamab resulted in a significantly higher incidence of TRAEs compared to osimertinib monotherapy and other combination regimens. Osimertinib with chemotherapy showed better PFS in almost all the subgroup analyses. In patients with brain metastases, osimertinib plus chemotherapy appeared to offer clinical benefits over other treatment strategies, although statistical significance was only observed in comparison with osimertinib monotherapy. Conclusion: This network meta-analysis suggests osimertinib plus pemetrexed-based chemotherapy as the only regimen demonstrating PFS benefits in the whole cohort and almost all the subgroup analyses, making it the optimal treatment for patients with advanced EGFR-mutated NSCLC. Given the higher incidence of grade ≥3 TRAEs, careful consideration is needed in clinical practice. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier, CRD42024579401.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.